Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Samsung Electronics (005930) – Decision on Cash and In-Kind Dividend / 2024-04-30

Posted on April 30, 2024July 29, 2026 By K-STOCK Editor No Comments on [Disclosure] Samsung Electronics (005930) – Decision on Cash and In-Kind Dividend / 2024-04-30

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Samsung Electronics has decided to pay a Q1 2024 cash dividend of KRW 361 per share for both common and preferred stocks, totaling approximately KRW 2.45T.

📊 [Summary of Key Disclosure Details & Figures]

  • Dividend Type: Quarterly Dividend (Q1 2024)
  • Form of Dividend: Cash Dividend
  • Dividend Per Share:
    • Common Stock: KRW 361
    • Preferred Stock: KRW 361
  • Dividend Yield:
    • Common Stock: 0.5%
    • Preferred Stock: 0.5%
  • Total Dividend Amount: KRW 2,452,153,599,250 (approx. KRW 2.45T)
  • Record Date: March 31, 2024
  • Scheduled Payment Date: May 20, 2024
  • Board Resolution Date: April 30, 2024 (Attended by all 6 Outside Directors and Audit Committee members)
  • General Shareholders’ Meeting: Not Held
  • Preferred Stock Details:
    • Samsung Electronics Pfd: Dividend per share KRW 361 / Dividend yield 0.5% / Total dividend amount KRW 297,062,098,700

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Dividend Payout Execution

Verifying whether the total cash dividend payout of approximately KRW 2.45T is executed without disruption on the scheduled payment date of May 20, 2024, is important to ensure the company’s shareholder return policy is carried out as planned. Related details on dividend disbursements can be verified in upcoming periodic reports (Annual, Quarterly, or Half-Year Reports).

📢 Disclaimer & Source Notice

Source: This content was structured and regenerated based on official filings submitted to the Financial Supervisory Service’s DART system.

Investment Risk Warning: This content is provided strictly for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific security. All investment decisions and financial liabilities rest entirely with the individual investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Semiconductors

Post navigation

Previous Post: [Disclosure] Hanwha Ocean (042660) Signs KRW 264.8B ‘Marine Product Performance Improvement Project’ Construction Contract with Affiliate Tidal Action LLC
Next Post: [Disclosure] Samsung Electronics (005930) – (Correction) Provisional Consolidated Financial Performance (Fair Disclosure) / 2024-04-30

Related Posts

[Disclosure] Jusung Engineering (036930) – (Correction) Sales and Supply Contract / 2024-08-14 Semiconductors
[Disclosure] ISU PETASYS(007660) – Decision on Cash/In-Kind Dividend / 2025-02-12 Disclosures
[Disclosure] Celltrion (068270) – Treasury Share Disposal Decision / 2025-04-23 Disclosures
[Disclosure] HPSP (403870) – Additional Listing (Exercise of Stock Options) / 2024-11-20 Semiconductors
[Disclosure] Hanmi Semiconductor (042700) – Investor Relations (IR) Holding / 2025-04-28 Semiconductors
[Disclosure] Hanwha Aerospace (012450) Reports Hanwha Ocean’s 100%-Owned Subsidiary Hanwha Ocean USA Holdings Corp. Concludes Paid-in Capital Increase, Amending Final Payment Date Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme